摘要
目的观察慢性乙型肝炎(chronic hepatitis B,CHB)患者阿德福韦酯(adefovir dipivoxil,ADV)抗病毒治疗前后外周血树突状细胞(dendritic cells,DC)和淋巴细胞亚群动态变化,探讨ADV抗HBV的免疫效应机制。方法对15例ADV抗病毒治疗有效的CHB患者动态观察1年,设健康对照组10例。在治疗前、治疗3个月、6个月和1年对外周血单核细胞源DC进行体外培养,流式细胞仪检测分析DC表面分子及淋巴细胞亚群水平。结果15例CHB患者均治疗持续有效。与治疗前比较,治疗3个月时DC表面分子CD1a、CD83、CD86和MHC-DR的表达无明显变化;治疗6个月和1年时上调,但二时相比较差异无显著性,且均低于健康对照组。淋巴细胞亚群于抗病毒3个月时亦无明显变化;治疗6个月和1年时,CD4+T及CD4+/CD8+T比值显著提高;NK比例虽有上升趋势,但与治疗前比较差异无显著性;CD3+T、CD8+T和CD19+B细胞未见明显改变。结论ADV治疗后CHB患者免疫增强,提示其可能通过调节DC和淋巴细胞亚群的功能而参与免疫应答,发挥间接抗病毒作用。
Objective To observe the dynamic changes of dendritic cells （DCs） and lymphocytes subsets from peripheral blood of patients with chronic hepatitis B （CHB） treated with adefovir dipivoxil（ADV） and explore the influ- ence on the cellular immunity after ADV therapy. Methods Fifteen CHB patients treated with ADV and ten health con- trois were included and followed up for one year in this study. DCs were isolated from peripheral blood and cultured in vitro at baseline, 3, 6 and 12 months. Subsequently, flow cytometry （FCM） was applied to quantify the surface markers of DCs and lymphocyte subsets. Results ADV antiviral therapy was consistently effective on the 15 patients. In compari- son with baseline, no signifiant change occurred at 3 months after ADV therapy. However, the expression level of CD1 a, CD83, CD86 and MHC - DR of DCs, as well as Cd4＋ T and CD4＋ / CD8 ＋ T cell ratio, was up - regulated at 6 months and 1 year, though still lower than those in control group. NK cell also increased, but there was no statistically significant difference compared with baseline. Furthermore no significant changes were found in CD3 ＋ T, CD8＋T and CD19 ＋B cell. Conclusion The immunity of CHB patients can be enhanced by ADV, suggesting that ADV possibly participate in the immune response through modulation of functions of DCs and lymphocytes subsets, thus play an indirect antivirus function.
出处
《广东医学》
CAS
CSCD
北大核心
2010年第1期72-74,共3页
Guangdong Medical Journal
基金
广东省自然科学基金博士科研启动基金资助项目(编号:07300964)
